NeuroPace (NPCE) announced a strategic refocusing of its product portfolio, terminating its SEEG products distribution relationship with DIXI Medical in Q4 2025. The company will maintain its focus on its core RNS System product line.
The company reaffirmed its 2025 revenue guidance and long-range plan expectations, including:20%+ revenue CAGR
Cash flow breakeven target by end of 2027
Gross margin improvement (RNS System >78% vs SEEG ~50%)
Key growth initiatives for 2026 include:Project CARE site of service expansion
Indication expansion into drug-resistant idiopathic generalized epilepsy
Expansion into pediatric focal epilepsy
Launch of AI-enabled software products
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.